Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert

Font Down Font Up
Mylan Posts Q3 Loss, Adj.EPS Beats View; Boosts FY09 EPS Forecast - Update
10/29/2009 8:29 AM ET


RELATED NEWS
Mylan Gets FDA Approval For Generic Version Of Acid Reflux Disease Drug Prevacid - Update
Mylan Subsidiary Receives FDA Approval For Generic Version Of Prevacid - Quick Facts
Mylan Q3 09 Earnings Conference Call At 10:00 AM
Mylan Slips To Loss In Q3; Lifts FY09 Adj. EPS View - Quick Facts
Dey Pharma Launches Newly Designed, Patient-friendly EpiPen Auto-Injector 0.3/0.15 Mg - Quick Facts
(RTTNews) - Generic drugmaker Mylan, Inc. (MYL: News ) Thursday reported a net loss for the third quarter, compared to profit last year, as the latest results included a hefty settlement related to Medicaid drug rebates. Adjusted earnings topped Wall Street expectation. Looking ahead, the company lifted its full-year adjusted earnings forecast above analysts' expectations.

The Canonsburg, Pennsylvania-based company posted its third-quarter net loss attributable to Mylan common shareholders of $40.02 million or $0.13 per share, compared to profit of $182.36 million or $0.47 per share in the same quarter last year. Previous year's results have been adjusted to reflect the adoption of FSP APB No. 14-1.

Excluding an $83 million after-tax charge related to the settlement of an investigation by the U.S. Department of Justice concerning Medicaid drug rebates, earnings for the quarter were $142.3 million or $0.32 per share. On average, 17 analysts polled by Thomson Reuters expected the company to report earnings of $0.27 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenues for the quarter declined to $1.264 billion from $1.656 billion in the prior year quarter. Analysts had a consensus revenue estimate of $1.23 billion for the quarter.

Net revenues rose to $1.256 billion from $1.191 billion, while Other revenues slumped to $8.37 million from $465.84 million reported last year.

Excluding $455.0 million of revenue related to the company's sale of the product rights of hypertension drug Bystolic that was included in 2008, total revenues increased by $62.2 million or 5.2% over the same prior year period. Year-over-year revenue growth on a constant currency basis would have been approximately 9%.
Generic revenues grew to $1.12 billion from $1.08 billion in the same prior year period. Specialty, consisting of Mylan's Dey business targeting the respiratory and severe allergy markets, reported third party revenues of $150.9 million, up from last year's $125.4 million.

Among generics, total revenues from North America rose to $502.5 million from $460.3 million for the same prior year period. Revenues from products launched in North America since September 30, 2008, and increased volume were primarily responsible for the increase in revenues, partially offset by unfavorable pricing due to additional generic competition on certain products. New products contributed revenues of about $60.0 million.

Total revenues from EMEA dropped to $417.6 million from $422.1 million in the previous year. Higher revenues in France, EMEA's largest market, and the U.K. served to offset lower revenue in Germany. The company noted that in France, revenues increased as a result of higher volumes and new product launches.

To receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print        

     
Top Stories
Wall Street Closes Lower For The Day, Mixed For The Week

Senate Democrats Fault GOP For Failing To Advance Alternative Health Reforms

New Guidelines Recommend Women Wait Until 21 For Cervical Cancer Screening

"New Moon" Takes Center Stage, Should Post Big Opening Weekend

Valero Energy To Permanently Shutter Delaware City Refinery - Update

Earnings
Escalon Medical Q1 Loss Widens - Quick Facts

Cordy Oilfield Services Q3 Net Loss Narrows - Quick Facts

Triton Energy Slips To Q3 Loss - Quick Facts

Electronic Game Card Revises Q3 Results - Quick Facts

Schneider Power Swings To Profit In Q3 - Quick Facts

US Market Commentary
Bay Street Stocks Slip Slightly Again - Canadian Commentary

Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary

Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary

Stocks Posting Moderate Losses In Early Afternoon Trading - U.S. Commentary

Stocks Seeing Further Downside In Late Morning Trading - U.S. Commentary

US Economic News
Fed's Fisher: "Too-Big-To-Fail" Must Be Addressed

Philly Fed Index Shows Much Bigger Than Expected Increase In November

Leading Indicators Index Increases For Seventh Straight Month In October

Philly Fed Index Jumps To 16.7 In November

Leading Indicators Index Rose 0.3% In October

Political News
Christian Leaders Unveil "Call To Faith" On Life, Marriage, Religious Freedom

Senate Ethics Committee Admonishes Burris But Finds No Legal Wrongdoing

Senate Democrats Fault GOP For Failing To Advance Alternative Health Reforms

Sen. Nelson Says He Will Vote To Proceed With Debate On Health Care Bill

Sen. Gregg Calls Ron Paul's Fed Audit Amendment "Political Pandering"




 
Markets End Week In Red
11/20/09 04:51
Partisan Debate Precedes Health Reform Vote
11/20/09 03:23
Wall Street Extends Losses
11/20/09 02:13
 

Today's Stocks to Watch
SVN - 7 Days Group Holdings Ltd.
SLW - Silver Wheaton Corp.
CPQQ.OB - China Power Equipment
LIMS - STARLIMS TECHNOLOGY
SPRD - Spreadtrum Communications Inc.
HEAT - SmartHeat Inc


Profit Taking Likely To Contribute To Continued Weakness – RTTNews Daily Market Analysis
The major index futures are currently indicating a notably lower open for stocks on Friday, with the markets likely to see some further downside after closing lower in each of the two previous sessions. With no major economic data on tap for the day, traders have looked to corporate news, including disappointing quarterly results from Dell (DELL). Traders may also continue to cash in on the recent strength in the markets that lifted the major averages to their best closing levels in over a year earlier in the week.

SLIDE SHOW: Pittsburgh Plays Host To Third G-20 Summit World leaders met at the G-20 summit in Pittsburgh, where they promised to maintain economic stimulus agreed to in London in April.
  Trading Center

 

Copyright © 2009 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service | How To Use RTTNews.com| Advertise| Buy Content | RSS